MDR is already taking in revenue from its pharmacy subscriptions is it not? 271k for the last quarter. There are already over 150k customers, 50 million prescriptions and has market penetration in 25% of all Australian pharmacies. In my mind that makes it more advanced than RAP, which is not making any revenue. HC's mcap includes performance shares, without which EV is only 19M. Brokers have only just got on this one (looking at the investor presentation and broker reports), when they pump this one up it will move far higher.
Buying MDR or MNQ around current market prices makes for a low risk entry. One of them will multibag eventually IMO. Of course, invest only risk capital but I think in a few months time shareholders will be quite pleased.
MDR is already taking in revenue from its pharmacy subscriptions...
Add to My Watchlist
What is My Watchlist?
